Assertio Collegium Agreement

Collegium is a specialty pharmaceutical company dedicated to managing responsibilities and pain. Collegium is headquartered in Stoughton, Massachusetts. For more information, please visit the company`s website at www.collegiumpharma.com. STOUGHTON, Mass., 06.02.2020 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to be the leader in pain management, today announced that it has reached a final agreement to acquire the U.S. rights to assertio Therapeutics, Inc.`s Nucynta franchise (“Assertio”) for $375.0 million in cash. Under the terms of the agreement, Collegium Assertio paid $375.0 million in cash for the closing, less royalties to Assertio in 2020. Collegium paid Assertio for certain stocks and equipment related to the products. As of January 9, 2018, (i) Collegium is responsible for the marketing of products in the United States, including sales and marketing, and (ii) the company receives royalties on all Collegium product revenues based on certain net sales thresholds, pursuant to the marketing agreement between the company and Collegium (as amended, the “Commercialization Agreement”). The marketing contract is terminated upon completion of certain provisions of the trade agreement that are in effect under the terms of the Asset Purchase Agreement.

Assertio Therapeutics is committed to finding responsible solutions to advance patient care in the company`s key areas of neurology, orphan drugs and specialty medicines. Assertio currently markets two FDA-approved products and continues to identify, license and develop new products that offer improved options for patients who may be under-supplied by existing therapies. For more information about Assertio, see www.assertiotx.com. Collegium will host a live conference call and audio webcast starting at 8:30 a.m.m Eastern Times (5:30 .m Pacific Time). To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to the conference ID: 668-9689. An audio webcast will be available on the company`s website via investor relations: www.collegiumpharma.com/. An archived webcast will be available on the company`s website approximately two hours after the event. Under the agreement, Collegium is exempt from paying royalties to Assertio. LAKE FOREST, ILL., February 13, 2020 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT) today announced the conclusion of the previously announced final agreement (“agreement”) with Collegium Pharmaceutical, Inc. (“Collegium”), according to which Le Collegium acquired NUCYNTA® of the product franchise. The company also announced today that it has fully repaid its priority guaranteed obligations.

In light of today`s agreement with Collegium, we have chosen to focus our employees, office size and location on our new business model. The company plans to move its headquarters from Newark, California, in mid-2018, and is currently exploring potential sites in the Midwest and East Coast. In line with this move, the company will reduce its workforce by 40% to about 70 employees and cover office supplies at headquarters by 50%. Depomed expects savings of approximately $10 million per year through the restructuring and relocation of headquarters. NEWARK, Calif., 04.12.2017 (GLOBE NEWSWIRE) — Depomed, Inc. (NASDAQ:DEPO) announced today that it has signed a definitive marketing agreement (“agreement”) with Collegium Pharmaceutical, Inc. (“Collegium”). Under the terms of the agreement, Collegium will market both NUCYNTA® Extended Release and NUCYNTA® The Version of Immediate Release (“NUCYNTA”). In exchange for Collegium`s marketing of NUCYNTA, Depomed receives a royalty rate for all nucynta transactions based on certain net revenue thresholds.